The analgesic effectiveness of perioperative lidocaine infusions for acute and chronic persistent postsurgical pain in patients undergoing breast cancer surgery: a systematic review and meta-analysis
Authors' conclusion
Our results provide moderate-quality evidence that perioperative lidocaine infusion does not reduce CPSP in patients undergoing breast cancer surgery.
Study context
- Population
- Patients undergoing breast cancer surgery
- Participants
- 1,039 patients · 13 RCTs
- Comparison
- Perioperative IV lidocaine infusion vs parenteral analgesia
- Lidocainen = 518
- Controln = 521reference
- Outcome
- Odds of CPSP (co-primary)
- Follow-up
- 3 and 6 months after operation
Methodological detailsHartung-Knapp-Sidik-Jonkman (HKSJ) random effects modelling
- HKSJ random effects modelling
Pooled result
As reported in the abstract
CPSP · 3 and 6 months
- Lidocaine did not decrease the odds of CPSP at 3 and 6 months vs control
Further pooled results
| Outcome | Mean difference (cm) (95% CI) | P value | |
|---|---|---|---|
| Postoperative pain · 1 hNot clinically important (1.1 cm threshold) | −0.65 (−0.73 to −0.57 cm) | P < 0.0001 | |
| −1−0.500.5Difference, cm (linear scale) |
| Outcome | Reduction (mg) (CI) | P value |
|---|---|---|
| Oral morphine consumption · first 24 hNot clinically important (30 mg threshold) | 7.06 (−13.19 to −0.93) | P = 0.029 |
Remaining secondary outcomes (incl. QoR, opioid-related and lidocaine side-effects)
- Groups not different
Original publication
The analgesic effectiveness of perioperative lidocaine infusions for acute and chronic persistent postsurgical pain in patients undergoing breast cancer surgery: a systematic review and meta-analysis. Br J Anaesth. Published 9 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →